Publication / Source: Bioanalysis 8(15)
Authors: Kaur S, Liu L, Cortes DF, Shao J, Jenkins R, Mylott Jr WR, Xu K
Background: Biotherapeutics development requires validated assays in biological matrices for pharmacokinetic assessment. Historically, ligand-binding assays have been the predominant platform available. Recently, alternative hybrid methods, combining ligand-binding analyte enrichment with LC–MS detection have emerged. Methodology & results: The validation of an immunoaffinity (IA)-LC–MS/MS method to quantify a monoclonal antibody biotherapeutic in cynomolgus monkey serum is described. This method includes immunoaffinity capture of the antibody in serum, followed by enzymatic digestion and detection of a framework peptide. Using similar method conditions, six additional biotherapeutic assays were readily validated in different nonhuman mammalian species, including mouse, rat and monkey. Conclusion: The immunoaffinity-LC–MS/MS assay validation results across seven antibody therapeutics, using comparable conditions, illustrate the ‘plug-and-play’ nature of the IA-LC–MS/MS mAb framework peptide assay format.